Evaluation of a modified live virus type-1a bovine viral diarrhea virus vaccine (Singer strain) against a type-2 (strain 890) challenge.
Both type-1 and type-2 bovine viral diarrhea virus (BVDV) infections are responsible for major losses in the cattle industry. However, several commercial BVDV vaccines contain only a type-1 strain. A vaccine trial was conducted to evaluate the efficacy of BVDV type-1 (Singer strain; BVDV-1) vaccine for protecting calves challenged with virulent BVDV type-2 (890 strain; BVDV-2). Thirty-eight BVDV-negative calves were randomly allocated to four groups. One group was treated with a modified live virus (MLV) BVDV-1 vaccine by i.m. injection and another group was treated with the same vaccine by s.c. injection. Two groups served as nonvaccinated controls (one i.m. and one s.c.). Twenty-eight days following vaccination, the calves were challenged with BVDV-2 and monitored for 21 days. Clinical scores and body temperatures of vaccinated calves were significantly (P<.05) lower than for controls on several days, and peak differences occurred 8 days after challenge. The control calves had significantly (P<.05) lower leukocyte counts 3 through 8 days after challenge; leukocyte counts for vaccinated animals did not decline significantly from prechallenge levels. There were no differences in protection between the i.m. and s.c. routes of vaccination. The study demonstrated satisfactory cross protection of the BVDV-1 vaccine against BVDV-2 challenge.
Fairbanks
Kris
K
Rural Technologies, Brookings, SD 57006, USA.
Schnackel
John
J
Chase
Christopher C L
CC
D000818:Animals; D001831:Body Temperature; D001835:Body Weight; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D002417:Cattle; D001908:Diarrhea Viruses, Bovine Viral / Q000145:classification* / Q000276:immunology* / Q000472:pathogenicity; D005260:Female; D007958:Leukocyte Count; D008297:Male; D013997:Time Factors; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*; D014774:Virulence
D014613:Vaccines, Attenuated; D014765:Viral Vaccines